Research conducted in Liberia into a vaccine for the deadly Ebola virus has been deemed successful.
The study investigated two separate vaccines that researchers found could protect against the haemorrhagic fever for at least one year.
The results of the trial, which involved 1 500 patients, were published in the New England Journal of Medicine.
They revealed that those given the vaccine developed a powerful antibody response to the virus, which lasted for about a year.
The success of the trial gives hope that both vaccines could be used to save lives should a future epidemic arise.
During an outbreak of the deadly disease in 2014 and 2015, more than 11 000 people died in Liberia, Sierra Leone and Guinea.